Global Liposomal Doxorubicin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Liposomal Doxorubicin Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Liposomal doxorubicin is a chemotherapy drug that is also called by the brand names Caelyx or Myocet. It contains the chemotherapy drug doxorubicin (Adriamycin) wrapped up in a fatty covering called a liposome. It is a treatment for some types of cancer, including: breast cancer, ovarian cancer, etc.

Liposomal Doxorubicin has an effect on a wide variety of tumor, belongs to the cycle non-specific drug, have all sorts of growth cycle of tumor cells to kill.it's given by injection into a vein.

Market Overview:

The latest research study on the global Liposomal Doxorubicin market finds that the global Liposomal Doxorubicin market reached a value of USD 783.55 million in 2022. It’s expected that the market will achieve USD 1027.05 million by 2028, exhibiting a CAGR of 4.61% during the forecast period.

Market Trends

The increasing use of drugs for breast cancer and liver cancer is expected to drive the growth of the Liposomal Doxorubicin market.
Breast cancer treatments have become the largest consumer of Liposomal Doxorubicin in the past few years. According to statistics, breast cancer treatment accounts for about 23.06% of the product's sales share. In the clinical medical community in North American countries, the adriamycin + cisplatin treatment scheme is currently used to treat breast cancer. With the high incidence of breast cancer in North America, the use of Liposomal Doxorubicin will be the biggest driver of its growth.
In addition, liver cancer treatment drugs are also one of the main users of
Liposomal Doxorubicin. According to foreign medical journal reports, doxorubicin can be used alone or in combination with cisplatin to treat liver cancer. Other chemotherapeutics are less effective against liver cancer.

Region Overview:

Asia Pacific had the highest growth rate of all regions.

Company Overview:

The top three companies are Johnson & Johnson, Sun Pharmaceutical, CSPC, with the revenue market share of 38.54%, 22.32% and 13.19% in 2019.

Johnson & Johnson announced on Dec. 20, 2019 that it will acquire Taris Biomedical, a Lexington, MA-based biotechnology company focused on drug delivery technology for the treatment of bladder diseases. Financial details were not disclosed.

Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200, a silicone-based drug delivery device that continuously releases medication into the bladder, according to a Taris press release.

Dedicated to shaping the next frontier of surgery, Johnson & Johnsoni (NYSE: JNJ) today announced an agreement to acquire the remaining stake in Verb Surgical Inc. following a successful strategic collaboration with Verily, an Alphabet company. Verb Surgical's world-class robotics and data science capabilities combined with Johnson & Johnson's health care leadership and global reach advance the company's vision to make medical interventions smarter, less invasive and more personalized.

Segmentation Overview:

Among different product types, 10 ml segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Breast Cancer segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Liposomal Doxorubicin market covered in Chapter 3:

Zydus Cadila
TTY Biopharma
Sun Pharmaceutical
Fudan-Zhangjiang
CSPC
Kinyond
Johnson & Johnson
Teva

In Chapter 4 and Chapter 14.2, on the basis of types, the Liposomal Doxorubicin market from 2018 to 2029 is primarily split into:

5 ml
10 ml
25 ml

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Liposomal Doxorubicin market from 2018 to 2029 covers:

Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)